Sular (Nisoldipine)
برای این دارو، اطلاعات عمومی (فارسی) یافت نشد . برای افزودن اطلاعات فارسی به این دارو کلیک نمایید.
Sular (Nisoldipine)

Sular
(nisoldipine) Extended Release Tablets

DRUG DESCRIPTION

SULAR ® (nisoldipine) is an extended release tablet dosage form of the dihydropyridine calcium channel blocker nisol- dipine. Nisoldipine is 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methyl- propyl ester, C20H24N2O6 , and has the structural formula:

SULAR ® (nisoldipine) structural formula illustration

Nisoldipine is a yellow crystalline substance, practically insoluble in water but soluble in ethanol. It has a molecular weight of 388.4. SULAR (nisoldipine) tablets consist of an external coat and an internal core. Both coat and core contain nisoldipine, the coat as a slow release formulation and the core as a fast release formulation. SULAR tablets contain either 10, 20, 30 or 40 mg of nisoldipine for once-a-day oral administration.

Inert ingredients in the formulation are: hydroxypropylcellulose, lactose, corn starch, crospovidone, microcrystalline cellulose, sodium lauryl sulfate, povidone and magnesium stearate. The inert ingredients in the film coating are: hypromellose, polyethylene glycol, ferric oxide, and titanium dioxide.

What are the possible side effects of nisoldipine (Sular)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • swelling in your legs or ankles;
  • chest pain;
  • fast or pounding heartbeats; or
  • feeling like you might pass out.

Less serious side effects may include:

  • dizziness;
  • warmth, redness, or tingly feeling under your skin;
  • headache;
  • nausea;
  • stuffy nose, sore throat;...

Read All Potential Side Effects and See Pictures of Sular »

What are the precautions when taking nisoldipine (Sular)?

Before taking nisoldipine, tell your doctor or pharmacist if you are allergic to it; or to other dihydropyridine calcium channel blockers (such as amlodipine, nifedipine); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: a certain structural heart problem (aortic stenosis).

Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver disease.

This drug may make you dizzy. Do not drive, use machinery, or do any activity that requires alertness until...

Read All Potential Precautions of Sular »

Last reviewed on RxList: 1/25/2008
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

SULAR (nisoldipine) is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

DOSAGE AND ADMINISTRATION

The dosage of SULAR (nisoldipine) must be adjusted to each patient's needs. Therapy usually should be initiated with 20 mg orally once daily, then increased by 10 mg per week or longer intervals, to attain adequate control of blood pressure. Usual maintenance dosage is 20 to 40 mg once daily. Blood pressure response increases over the 10 - 60 mg daily dose range but adverse event rates also increase. Doses beyond 60 mg once daily are not recommended. SULAR (nisoldipine) has been used safely with diuretics, ACE inhibitors, and beta-blocking agents. Patients over age 65, or patients with impaired liver function are expected to develop higher plasma concentrations of nisoldipine. Their blood pressure should be monitored closely during any dosage adjustment. A starting dose not exceeding 10 mg daily is recommended in these patient groups. SULAR (nisoldipine) tablets should be administered orally once daily. Administration with a high fat meal can lead to excessive peak drug concentration and should be avoided. Grapefruit products should be avoided before and after dosing. SULAR (nisoldipine) is an extended release dosage form and tablets should be swallowed whole, not bitten, divided or crushed.

HOW SUPPLIED

SULAR (nisoldipine) extended release tablets are supplied as 10 mg, 20 mg, 30 mg, and 40 mg round film coated tablets. The different strengths can be identified as follows:

Strength Color Markings
10 mg Oyster 440 on one side and FH 10 on the other side.
20 mg Yellow Cream 441 on one side and FH 20 on the other side.
30 mg Mustard 442 on one side and FH 30 on the other side.
40 mg Burnt Orange 443 on one side and FH 40 on the other side.

SULAR (nisoldipine) Tablets are supplied in:

  Strength NDC Code
Bottles of 100 10 mg
20 mg
30 mg
40 mg
59630-440-10
59630-441-10
59630-442-10
59630-443-10

Protect from light and moisture. Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Dispense in tight, light-resistant containers.

SULAR (nisoldipine) is a trademark of Sciele™ Pharma, Inc. Manufactured for: Sciele™ Pharma, Inc. Atlanta, GA 30328. By: Bayer AG, Leverkusen, Germany. FDA Rev date: 1/2/2008

Last reviewed on RxList: 1/25/2008
This monograph has been modified to include the generic and brand name in many instances.

SIDE EFFECTS

More than 6000 patients world-wide have received nisoldipine in clinical trials for the treatment of hypertension, either as the immediate release or the SULAR (nisoldipine) extended release formulation. Of about 1,500 patients who received SULAR (nisoldipine) in hypertension studies, about 55% were exposed for at least 2 months and about one third were exposed for over 6 months, the great majority at doses of 20 to 60 mg daily.

SULAR (nisoldipine) is generally well-tolerated. In the U.S. clinical trials of SULAR (nisoldipine) in hypertension, 10.9% of the 921 SULAR (nisoldipine) patients discontinued treatment due to adverse events compared with 2.9% of 280 placebo patients. The frequency of discontinuations due to adverse experiences was related to dose, with a 5.4% discontinuation rate at 10 mg daily and a 10.9% discontinuation rate at 60 mg daily.

The most frequently occurring adverse experiences with SULAR (nisoldipine) are those related to its vasodilator properties; these are generally mild and only occasionally lead to patient withdrawal from treatment. The table below, from U.S. placebo-controlled parallel dose response trials of SULAR (nisoldipine) using doses from 10 - 60 mg once daily in patients with hypertension, lists all of the adverse events, regardless of the causal relationship to SULAR (nisoldipine) , for which the overall incidence on SULAR (nisoldipine) was both > 1% and greater with SULAR (nisoldipine) than with placebo.

Adverse Event Nisoldipine (%)
(n=663)
Placebo (%)
(n=280)
Peripheral Edema 22 10
Headache 22 15
Dizziness 5 4
Pharyngitis 5 4
Vasodilation 4 2
Sinusitis 3 2
Palpitation 3 1
Chest Pain 2 1
Nausea 2 1
Rash 2 1

Only peripheral edema and possibly dizziness appear to be dose related.

Adverse Event SULAR
Placebo 10mg 20mg 30mg 40mg 60mg
(Rates in %) N=280 N=30 N=170 N=105 N=139 N=137
Peripheral Edema 10 7 15 20 27 29
Dizziness 4 7 3 3 4 10

The common adverse events occurred at about the same rate in men as in women, and at a similar rate in patients over age 65 as in those under that age, except that headache was much less common in older patients. Except for peripheral edema and vasodilation, which were more common in whites, adverse event rates were similar in blacks and whites.

The following adverse events occurred in ≤ 1% of all patients treated for hypertension in U.S. and foreign clinical trials, or with unspecified incidence in other studies. Although a causal relationship of SULAR (nisoldipine) to these events cannot be established, they are listed to alert the physician to a possible relationship with SULAR (nisoldipine) treatment.

Body As A Whole: cellulitis, chills, facial edema, fever, flu syndrome, malaise

Cardiovascular: atrial fibrillation, cerebrovascular accident, congestive heart failure, first degree AV block, hypertension, hypotension, jugular venous distension, migraine, myocardial infarction, postural hypotension, ventricular extrasystoles, supraventricular tachycardia, syncope, systolic ejection murmur, T wave abnormalities on ECG (flattening, inversion, nonspecific changes), venous insufficiency

Digestive: abnormal liver function tests, anorexia, colitis, diarrhea, dry mouth, dyspepsia, dysphagia, flatulence, gastritis, gastrointestinal hemorrhage, gingival hyperplasia, glossitis, hepatomegaly, increased appetite, melena, mouth ulceration

Endocrine: diabetes mellitus, thyroiditis

Hemic and Lymphatic: anemia, ecchymoses, leukopenia, petechiae

Metabolic and Nutritional: gout, hypokalemia, increased serum creatine kinase, increased nonprotein nitrogen, weight gain, weight loss

Musculoskeletal: arthralgia, arthritis, leg cramps, myalgia, myasthenia, myositis, tenosynovitis

Nervous: abnormal dreams, abnormal thinking and confusion, amnesia, anxiety, ataxia, cerebral ischemia, decreased libido, depression, hypesthesia, hypertonia, insomnia, nervousness, paresthesia, somnolence, tremor, vertigo

Respiratory: asthma, dyspnea, end inspiratory wheeze and fine rales, epistaxis, increased cough, laryngitis, pharyngitis, pleural effusion, rhinitis, sinusitis

Skin and Appendages: acne, alopecia, dry skin, exfoliative dermatitis, fungal dermatitis, herpes simplex, herpes zoster, maculopapular rash, pruritus, pustular rash, skin discoloration, skin ulcer, sweating, urticaria

Special Senses: abnormal vision, amblyopia, blepharitis, conjunctivitis, ear pain, glaucoma, itchy eyes, keratoconjunctivitis, otitis media, retinal detachment, tinnitus, watery eyes, taste disturbance, temporary unilateral loss of vision, vitreous floater

Urogenital: dysuria, hematuria, impotence, nocturia, urinary frequency, increased BUN and serum creatinine, vaginal hemorrhage, vaginitis.

The following postmarketing event has been reported very rarely in patients receiving SULAR (nisoldipine) : systemic hypersensitivity reaction which may include one or more of the following; angioedema, shortness of breath, tachycardia, chest tightness, hypotension, and rash. A definite causal relationship with SULAR (nisoldipine) has not been established. An unusual event observed with immediate release nisoldipine but not observed with SULAR (nisoldipine) was one case of photosensitivity. Gynecomastia has been associated with the use of calcium channel blockers.

Read the Sular (nisoldipine) Side Effects Center for a complete guide to possible side effects »

DRUG INTERACTIONS

A 30 to 45% increase in AUC and C max of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily. Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15 - 20 %). No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.

Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels. Coadministration of SULAR (nisoldipine) with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered. Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant. Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine. The blood pressure effect of SULAR (nisoldipine) tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration. The immedi- ate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%. This interaction was not accompanied by ECG changes and its clinical significance is not known. No significant inter- actions were found between nisoldipine and warfarin or digoxin.

Last reviewed on RxList: 2/7/2008
This monograph has been modified to include the generic and brand name in many instances.

WARNINGS

Increased angina and/or myocardial infarction in patients with coronary artery disease: Rarely, patients particularly those with severe obstructive coronary artery disease, have developed increased frequency, duration and/or severity of angina, or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase. The mechanism of this effect has not been established. In controlled studies of SULAR (nisoldipine) in patients with angina this was seen about 1.5% of the time in patients given nisoldipine, compared with 0.9% in patients given placebo.

PRECAUTIONS

General

Hypotension: Because nisoldipine, like other vasodilators, decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of SULAR (nisoldipine) is recommended. Close observation is especially important for patients already taking medications that are known to lower blood pressure.

Although in most patients the hypotensive effect of SULAR (nisoldipine) is modest and well tolerated, occasional patients have had excessive and poorly tolerated hypotension. These responses have usually occurred during initial titration or at the time of subsequent upward dosage adjustment.

Congestive Heart Failure:Although acute hemodynamic studies of nisoldipine in patients with NYHA Class II-IV heart failure have not demonstrated negative inotropic effects, safety of SULAR (nisoldipine) in patients with heart failure has not been established. Caution therefore should be exercised when using SULAR (nisoldipine) in patients with heart failure or compromised ventricular function, particularly in combination with a beta-blocker.

Patients with Hepatic Impairment: Because nisoldipine is extensively metabolized by the liver and, in patients with cirrhosis, it reaches blood concentrations about 5 times those in normals, SULAR (nisoldipine) should be administered cautiously in patients with severe hepatic dysfunction (See DOSAGE AND ADMINISTRATION).

Laboratory Tests:SULAR (nisoldipine) is not known to interfere with the interpretation of laboratory tests.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Dietary administration of nisoldipine to male and female rats for up to 24 months (mean doses up to 82 and 111 mg/kg/day, 16 and 19 times the maximum recommended human dose {MRHD} on a mg/m2 basis, respectively) and female mice for up to 21 months (mean doses of up to 217 mg/kg/day, 20 times the MRHD on a mg/m2 basis) revealed no evidence of tumorigenic effect of nisoldipine. In male mice receiving a mean dose of 163 mg nisoldipine/kg/day (16 times the MRHD of 60 mg/day on a mg/m2 basis), an increased frequency of stomach papilloma, but still within the historical range, was observed. No evidence of stomach neoplasia was observed at lower doses (up to 58 mg/kg/day). Nisoldipine was negative when tested in a battery of genotoxicity assays including the Ames test and the CHO/HGRPT assay for mutagenicity and the in vivo mouse micronucleus test and in vitro CHO cell test for clastogenicity.

When administered to male and female rats at doses of up to 30 mg/kg/day (about 5 times the MRHD on a mg/m2 basis) nisoldipine had no effect on fertility.

Pregnancy Category C: Nisoldipine was neither teratogenic nor fetotoxic at doses that were not maternally toxic. Nisoldipine was fetotoxic but not teratogenic in rats and rabbits at doses resulting in maternal toxicity (reduced maternal body weight gain). In pregnant rats, increased fetal resorption (postimplantation loss) was observed at 100 mg/kg/day and decreased fetal weight was observed at both 30 and 100 mg/kg/day. These doses are, respectively, about 5 and 16 times the MRHD when compared on a mg/m2 basis. In pregnant rabbits, decreased fetal and placental weights were observed at a dose of 30 mg/kg/day, about 10 times the MRHD when compared on a mg/m2 basis. In a study in which pregnant monkeys (both treated and control) had high rates of abortion and mortality, the only surviving fetus from a group exposed to a maternal dose of 100 mg nisoldipine/ kg/day (about 30 times the MRHD when compared on a mg/m2 basis) presented with forelimb and vertebral abnormalities not previously seen in control monkeys of the same strain. There are no adequate and well controlled studies in pregnant women. SULAR (nisoldipine) should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers:It is not known whether nisoldipine is excreted in human milk. Because many drugs are excreted in human milk, a decision should be made to discontinue nursing, or to discontinue SULAR (nisoldipine) , taking into account the importance of the drug to the mother.

Pediatric Use:Safety and effectiveness in pediatric patients have not been established.

Geriatric Use:Clinical studies of nisoldipine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Patients over 65 are expected to develop higher plasma concentrations of nisoldipine. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

Last reviewed on RxList: 2/7/2008
This monograph has been modified to include the generic and brand name in many instances.

OVERDOSE

There is no experience with nisoldipine overdosage. Generally, overdosage with other dihydropyridines leading to pronounced hypotension calls for active cardiovascular support including monitoring of cardiovascular and respiratory function, elevation of extremities, judicious use of calcium infusion, pressor agents and fluids. Clearance of nisoldipine would be expected to be slowed in patients with impaired liver function. Since nisoldipine is highly protein bound, dialysis is not likely to be of any benefit; however, plasmapheresis may be beneficial.

CONTRAINDICATIONS

SULAR (nisoldipine) is contraindicated in patients with known hypersensitivity to dihydropyridine calcium channel blockers.

Last reviewed on RxList: 1/25/2008
This monograph has been modified to include the generic and brand name in many instances.

CLINICAL PHARMACOLOGY

Mechanism of Action

Nisoldipine is a member of the dihydropyridine class of calcium channel antagonists (calcium ion antagonists or slow channel blockers) that inhibit the transmembrane influx of calcium into vascular smooth muscle and cardiac muscle. It reversibly competes with other dihydropyridines for binding to the calcium channel. Because the contractile process of vascular smooth muscle is dependent upon the movement of extracellular calcium into the muscle through specific ion channels, inhibition of the calcium channel results in dilation of the arterioles. In vitro studies show that the effects of nisoldipine on contractile processes are selective, with greater potency on vascular smooth muscle than on cardiac muscle. Although, like other dihydropyridine calcium channel blockers, nisoldipine has negative inotropic effects in vitro, studies conducted in intact anesthetized animals have shown that the vasodilating effect occurs at doses lower than those that affect cardiac contractility.

The effect of nisoldipine on blood pressure is principally a consequence of a dose-related decrease of peripheral vascular resistance. While nisoldipine, like other dihydropyridines, exhibits a mild diuretic effect, most of the antihypertensive activity is attributed to its effect on peripheral vascular resistance.

Pharmacokinetics and Metabolism

Nisoldipine pharmacokinetics are independent of the dose in the range of 20 to 60 mg, with plasma concentrations proportional to dose. Nisoldipine accumulation, during multiple dosing, is predictable from a single dose. Nisoldipine is relatively well absorbed into the systemic circulation with 87% of the radiolabeled drug recovered in urine and feces. The absolute bioavailability of nisoldipine is about 5%. Nisoldipine's low bioavailability is due, in part to pre-systemic metabolism in the gut wall, and this metabolism decreases from the proximal to the distal parts of the intestine. Food with a high fat content has a pronounced effect on the release of nisoldipine from the coat-core formulation and results in a significant increase in peak concentration (C max ) by up to 300%. Total exposure, however is decreased about 25%, presumably because more of the drug is released proximally. This effect appears to be specific for nisoldipine in the controlled release formulation, as a less pronounced food effect was seen with the immediate release tablet. Concomitant intake of a high fat meal with SULAR (nisoldipine) should be avoided. Maximal plasma concentrations of nisoldipine are reached 6 to 12 hours after dosing. The terminal elimination half-life (reflecting post absorption clearance of nisoldipine) ranges from 7 to 12 hours. C max and AUC increase by factors of approximately 1.3 and 1.5, respectively, from first dose to steady state. After oral administration, the concentration of (+) nisoldipine, the active enantiomer, is about 6 times higher than the (-) inactive enantiomer The plasma protein binding of nisoldipine is very high, with less than 1% unbound over the plasma concentration range of 100 ng/mL to 10 mcg/mL.

Nisoldipine is highly metabolized; 5 major urinary metabolites have been identified. Although 60 - 80% of an oral dose undergoes urinary excretion, only traces of unchanged nisoldipine are found in urine. The major biotransformation pathway appears to be the hydroxylation of the isobutyl ester. A hydroxylated derivative of the side chain, present in plasma at concentrations approximately equal to the parent compound, appears to be the only active metabolite, and has about 10% of the activity of the parent compound. Cytochrome P 450 enzymes are believed to play a major role in the metabolism of nisoldipine. The particular isoenzyme system responsible for its metabolism has not been identified, but other dihydropyridines are metabolized by cytochrome P 450 IIIA4. Nisoldipine should not be administered with grapefruit juice as this has been shown, in a study of 12 subjects, to interfere with nisoldipine metabolism, resulting in a mean increase in C max of about 3-fold (ranging up to about 7-fold) and AUC of almost 2-fold (ranging up to about 5-fold). A similar phenomenon has been seen with several other dihydropyridine calcium channel blockers.

Special Populations

Renal Dysfunction: Because renal elimination is not an important pathway, bioavailability and pharmacokinetics of SULAR (nisoldipine) were not significantly different in patients with various degrees of renal impairment. Dosing adjustments in patients with mild to moderate renal impairment are not necessary.

Geriatric: Elderly patients have been found to have 2 to 3 fold higher plasma concentrations (Cmax and AUC) than young subjects. This should be reflected in more cautious dosing (See DOSAGE AND ADMINISTRATION).

Hepatic Insufficiency: In patients with liver cirrhosis given 10 mg SULAR (nisoldipine) , plasma concentrations of the parent compound were 4 to 5 times higher than those in healthy young subjects. Lower starting and maintenance doses should be used in cirrhotic patients (See DOSAGE AND ADMINISTRATION).

Gender and Race: The effect of gender or race on the pharmacokinetics of nisoldipine has not been investigated.

Disease States: Hypertension does not significantly alter the pharmacokinetics of nisoldipine.

Pharmacodynamics

Hemodynamic Effects

Administration of a single dose of nisoldipine leads to decreased systemic vascular resistance and blood pressure with a transient increase in heart rate. The change in heart rate is greater with immediate release nisoldipine preparations. The effect on blood pressure is directly related to the initial degree of elevation above normal. Chronic administration of nisoldipine results in a sustained decrease in vascular resistance and small increases in stroke index and left ventricular ejection fraction. A study of the immediate release formulation showed no effect of nisoldipine on the renin-angiotensin-aldosterone system or on plasma norepinephrine concentration in normals. Changes in blood pressure in hypertensive patients given SULAR (nisoldipine) were dose related over the range of 10 - 60 mg/day. Nisoldipine does not appear to have significant negative inotropic activity in intact animals or humans, and did not lead to worsening of clinical heart failure in three small studies of patients with asymptomatic and symptomatic left ventricular dysfunction. There is little information, however, in patients with severe congestive heart failure, and all calcium channel blockers should be used with caution in any patient with heart failure.

Electrophysiologic Effects

Nisoldipine has no clinically important chronotropic effects. Except for mild shortening of sinus cycle, SA conduc- tion time and AH intervals, single oral doses up to 20 mg of immediate release nisoldipine did not significantly change other conduction parameters. Similar electrophysiologic effects were seen with single iv doses, which could be blunted in patients pre-treated with beta-blockers. Dose and plasma level related flattening or inversion of T-waves have been observed in a few small studies. Such reports were concentrated in patients receiving rapidly increased high doses in one study; the phenomenon has not been a cause of safety concern in large clinical trials.

Clinical Studies in Hypertension

The antihypertensive efficacy of SULAR (nisoldipine) was studied in 5 double-blind, placebo-controlled, randomized studies, in which over 600 patients were treated with SULAR (nisoldipine) as monotherapy and about 300 with placebo; 4 of the five studies compared 2 or 3 fixed doses while the fifth allowed titration from 10 - 40 mg. Once daily administration of SULAR (nisoldipine) produced sustained reductions in systolic and diastolic blood pressures over the 24 hour dosing interval in both supine and standing positions. The mean placebo-subtracted reductions in supine systolic and diastolic blood pressure at trough, 24 hours post-dose, in these studies, are shown below. Changes in standing blood pressure were similar:

MEAN SUPINE TROUGH SYSTOLIC AND DIASTOLIC BLOOD PRESSURE CHANGES (mm Hg)


SULAR Dose
(mg/day)
10
mg
20
mg
30
mg
40
mg
60
mg
10-40
mg titrated
Systolic 8 11 11 14 15 15
Diastolic 3 5 7 7 10 8

In patients receiving atenolol, supine blood pressure reductions with SULAR (nisoldipine) at 20, 40 and 60 mg once daily were 12/6, 19/8 and 22/10 mm Hg, respectively. The sustained antihypertensive effect of SULAR (nisoldipine) was demonstrated by 24 hour blood pressure monitoring and examination of peak and trough effects. The trough/peak ratios ranged from 70 to 100% for diastolic and systolic blood pressure. The mean change in heart rate in these studies was less than one beat per minute. In 4 of the 5 studies, patients received initial doses of 20 - 30 mg SULAR (nisoldipine) without incident (excessive effects on blood pressure or heart rate). The fifth study started patients on lower doses of SULAR (nisoldipine) . Patient race and gender did not influence the blood pressure lowering effect of SULAR. Despite the higher plasma concentration of nisoldipine in the elderly, there was no consistent difference in their blood pressure response except that the 10 mg dose was somewhat more effective than in non-elderly patients. No postural effect on blood pressure was apparent and there was no evidence of tolerance to the antihypertensive effect of SULAR (nisoldipine) in patients treated for up to one year.

Last reviewed on RxList: 2/7/2008
This monograph has been modified to include the generic and brand name in many instances.

PATIENT INFORMATION

SULAR (nisoldipine) is an extended release tablet and should be swallowed whole. Tablets should not be chewed, divided or crushed. SULAR (nisoldipine) should not be administered with a high fat meal. Grapefruit juice, which has been shown to increase significantly the bioavailability of nisoldipine and other dihydropyridine type calcium channel blockers, should not be taken with SULAR (nisoldipine) .

Last reviewed on RxList: 1/25/2008
This monograph has been modified to include the generic and brand name in many instances.

>

PATIENT INFORMATION

SULAR (nisoldipine) is an extended release tablet and should be swallowed whole. Tablets should not be chewed, divided or crushed. SULAR (nisoldipine) should not be administered with a high fat meal. Grapefruit juice, which has been shown to increase significantly the bioavailability of nisoldipine and other dihydropyridine type calcium channel blockers, should not be taken with SULAR (nisoldipine) .

Last reviewed on RxList: 1/25/2008
This monograph has been modified to include the generic and brand name in many instances.

Disclaimer

Sular Consumer

IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

NISOLDIPINE (8.5, 17, 25.5, OR 34 MG) SUSTAINED ACTION - ORAL

(nye-SOL-di-peen)

COMMON BRAND NAME(S): Sular

USES: Nisoldipine is used with or without other medications to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Nisoldipine is called a calcium channel blocker. It works by relaxing blood vessels so blood can flow more easily.

HOW TO USE: Take this medication by mouth, usually once daily or as directed by your doctor. Take this medication on an empty stomach 1 hour before or 2 hours after a meal.

Do not crush or chew this medication. Doing so can release all of the drug at once, increasing the risk of side effects. Also, do not split the tablets unless they have a score line and your doctor or pharmacist tells you to do so. Swallow the whole or split tablet without crushing or chewing.

This medication comes in different sustained-action forms with different strengths. Check with your doctor or pharmacist that you are taking the correct dose and form. Do not take a different strength or form without checking with your doctor or pharmacist first.

Avoid eating grapefruit or drinking grapefruit juice while using this medication unless your doctor instructs you otherwise. Grapefruit can increase the amount of certain medications in your bloodstream. Consult your doctor or pharmacist for more details.

The dosage is based on your medical condition and response to treatment. Your doctor may gradually increase your dose. Follow your doctor's instructions carefully.

Use this medication regularly to get the most benefit from it. To help you remember, take it at the same time each day. It is important to continue taking this medication even if you feel well. Most people with high blood pressure do not feel sick.

Tell your doctor if your condition does not improve or if it worsens (for example, your routine blood pressure readings remain high or increase).

Disclaimer

Sular Consumer (continued)

SIDE EFFECTS: Dizziness, swelling ankles/feet, flushing, or headache may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

To reduce dizziness and lightheadedness, get up slowly when rising from a sitting or lying position.

An empty tablet shell may appear in your stool. This effect is harmless because your body has already absorbed the medication.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor immediately if any of these unlikely but serious side effects occur: fast/irregular/pounding heartbeat, fainting.

Tell your doctor immediately if any of these rare but very serious side effects occur: vision changes.

A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the Sular (nisoldipine) Side Effects Center for a complete guide to possible side effects »

PRECAUTIONS: Before taking nisoldipine, tell your doctor or pharmacist if you are allergic to it; or to other dihydropyridine calcium channel blockers (such as amlodipine, nifedipine); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: a certain structural heart problem (aortic stenosis).

Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver disease.

This drug may make you dizzy. Do not drive, use machinery, or do any activity that requires alertness until you are sure you can perform such activities safely. Limit alcoholic beverages.

Before having surgery, tell your doctor or dentist that you are taking this medication.

During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.

It is not known if this medication passes into breast milk. Consult your doctor before breast-feeding.

Disclaimer

Sular Consumer (continued)

DRUG INTERACTIONS: See also the How to Use section.

Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor or pharmacist first.

This drug should not be used with the following medication because a very serious interaction may occur: phenytoin.

If you are currently using phenytoin, tell your doctor or pharmacist before starting nisoldipine.

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use.

Other medications can affect the removal of nisoldipine from your body, which may affect how nisoldipine works. Examples include cimetidine, azole antifungals (such as itraconazole), macrolide antibiotics (such as erythromycin), rifamycins (such as rifabutin), St. John's wort, drugs used to treat seizures (such as carbamazepine, phenytoin), among others.

Check the labels on all your medicines (such as cough-and-cold products, diet aids, nonsteroidal anti-inflammatory drugs-NSAIDs for pain/fever reduction) because they may contain ingredients that could increase your blood pressure or heart rate (such as pseudoephedrine, phenylephrine, ibuprofen, naproxen). Ask your pharmacist about using those products safely.

Cimetidine is a nonprescription drug that is commonly used to treat extra stomach acid. Because cimetidine may interact with nisoldipine, ask your pharmacist about other products to treat stomach acid.

This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

OVERDOSE: If overdose is suspected, contact your local poison control center or emergency room immediately. US residents can call the US National Poison Hotline at 1-800-222-1222. Canada residents can call a provincial poison control center.

NOTES: Do not share this medication with others. Talk with your doctor about making lifestyle changes that may help this medication work better (such as stress reduction programs, exercise, and dietary changes).

Laboratory and/or medical tests (such as liver function tests, heart exam, blood pressure) may be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.

Have your blood pressure checked regularly while taking this medication. Learn how to monitor your own blood pressure at home, and share the results with your doctor.

MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

STORAGE: Store at room temperature between 68-77 degrees F (20-25 degrees C) away from light and moisture. Brief storage between 59-86 degrees F (15-30 degrees C) is permitted. Do not store in the bathroom. Keep all medicines away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

MEDICAL ALERT: Your condition can cause complications in a medical emergency. For enrollment information call MedicAlert at 1-800-854-1166 (USA) or 1-800-668-1507 (Canada).

Information last revised July 2010. Copyright(c) 2010 First Databank, Inc.

Sular Patient Information Including Side Effects

Brand Names: Sular

Generic Name: nisoldipine (Pronunciation: nye ZOL di peen)

What is nisoldipine (Sular)?

Nisoldipine is in a group of drugs called calcium channel blockers. Nisoldipine relaxes (widens) blood vessels and improves blood flow.

Nisoldipine is used to treat high blood pressure (hypertension).

Nisoldipine may also be used for other purposes not listed in this medication guide.

Nisoldipine 20 mg-MYL

round, beige, imprinted with M, N 22

Nisoldipine 30 mg-MYL

round, orange, imprinted with M, N 23

Nisoldipine 40 mg-MYL

round, yellow, imprinted with M, N 24

Sular 10 mg

round, yellow, imprinted with ZENECA 10, 891

Sular 10 mg-FOR

round, gray, imprinted with 440, FH 10

Sular 20 mg

round, yellow, imprinted with ZENECA 20, 892

Sular 20 mg-FOR

round, yellow, imprinted with 441, FH 20

Sular 30 mg

round, gold, imprinted with 893, ZENECA 30

Sular 30 mg-FOR

round, gold, imprinted with 442, FH 30

Sular 40 mg

round, orange, imprinted with 894, ZENECA 40

Sular 40 mg-FOR

round, orange, imprinted with 443, FH 40

What are the possible side effects of nisoldipine (Sular)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • swelling in your legs or ankles;
  • chest pain;
  • fast or pounding heartbeats; or
  • feeling like you might pass out.

Less serious side effects may include:

  • dizziness;
  • warmth, redness, or tingly feeling under your skin;
  • headache;
  • nausea;
  • stuffy nose, sore throat; or
  • mild skin rash.

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

Read the Sular (nisoldipine) Side Effects Center for a complete guide to possible side effects »

What is the most important information I should know about nisoldipine (Sular)?

You should not use this medication if you are allergic to nisoldipine, or to similar medications such as amlodipine (Norvasc), felodipine (Plendil), nicardipine (Cardene), nifedipine (Procardia, Adalat), or nimodipine (Nimotop).

Before using nisoldipine, tell your doctor if you are allergic to any drugs, or if you have coronary artery disease, congestive heart failure, or liver disease.

Take nisoldipine on an empty stomach, at least 1 hour before or 2 hours after a meal. Avoid eating grapefruit or drinking grapefruit juice when you take nisoldipine.

Call your doctor at once if you have a serious side effect such as swelling in your legs or ankles, chest pain, fast or pounding heartbeats, or if you feel like you might pass out.

Keep using this medicine as directed, even if you feel well. High blood pressure often has no symptoms, so you may not know when your blood pressure is high. You may need to use blood pressure medication for the rest of your life.

Side Effects Centers

Sular Patient Information including How Should I Take

What should I discuss with my healthcare provider before taking nisoldipine (Sular)?

You should not use this medication if you are allergic to nisoldipine, or to similar medications such as amlodipine (Norvasc), felodipine (Plendil), nicardipine (Cardene), nifedipine (Procardia, Adalat), or nimodipine (Nimotop).

Before using nisoldipine, tell your doctor if you are allergic to any drugs, or if you have:

  • coronary artery disease;
  • congestive heart failure; or
  • liver disease.

If you have any of these conditions, you may need a dose adjustment or special tests to safely take this medication.

FDA pregnancy category C. It is not known whether nisoldipine is harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.

It is not known if nisoldipine passes into breast milk or if it could harm a nursing infant. Do not take nisoldipine without telling your doctor if you are breast-feeding a baby.

How should I take nisoldipine (Sular)?

Take nisoldipine exactly as it was prescribed for you. Do not take it in larger doses or for longer than recommended by your doctor. Follow the directions on your prescription label.

Take nisoldipine on an empty stomach, at least 1 hour before or 2 hours after a meal.

Do not crush, chew, or break an extended-release tablet. Swallow the pill whole. Breaking the pill may cause too much of the drug to be released at one time.

To be sure this medication is helping your condition, your blood pressure will need to be tested on a regular basis. Do not miss any scheduled visits to your doctor.

Keep using this medicine as directed, even if you feel well. High blood pressure often has no symptoms, so you may not know when your blood pressure is high. You may need to use blood pressure medication for the rest of your life.

Store nisoldipine at room temperature away from moisture and heat.

Side Effects Centers

Sular Patient Information including If I Miss a Dose

What happens if I miss a dose (Sular)?

Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at the next regularly scheduled time. Do not take extra medicine to make up the missed dose.

What happens if I overdose (Sular)?

Seek emergency medical attention if you think you have used too much of this medicine.

Overdose symptoms may include dizziness or fainting.

What should I avoid while taking nisoldipine (Sular)?

Avoid eating grapefruit or drinking grapefruit juice when you take nisoldipine.

What other drugs will affect nisoldipine (Sular)?

Tell your doctor about all other medications you use, especially:

  • other blood pressure medications;
  • armodafanil (Nuvigil) or modafanil (Progivil);
  • cimetidine (Tagamet);
  • conivaptan (Vaprisol);
  • dexamethasone (Decadron, Hexadrol);
  • an antibiotic such as clarithromycin (Biaxin), erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin), griseofulvin (Fulvicin, Grifulvin, Grisactin), telithromycin (Ketek), or troleandomycin (Tao);
  • an antifungal medication such as clotrimazole (Mycelex Troche), itraconazole (Sporanox), ketoconazole (Nizoral), or voriconazole (Vfend);
  • rifabutin (Mycobutin), rifampin (Rifadin, Rifater, Rifamate), or rifapentine (Priftin);
  • St. John's wort;
  • an antidepressant such as nefazodone, paroxetine (Paxil), or sertraline (Zoloft);
  • a barbiturate such as amobarbital (Amytal), butabarbital (Butisol), mephobarbital (Mebaral), secobarbital (Seconal), or phenobarbital (Luminal, Solfoton);
  • HIV medication such as atazanavir (Reyataz), delavirdine (Rescriptor), efavirenz (Sustiva), etravirine (Intelence), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), ritonavir (Norvir, Kaletra), or saquinavir (Invirase); or
  • seizure medication such as carbamazepine (Carbatrol, Tegretol), felbamate (Felbatol), oxcarbazepine (Trileptal), or phenytoin (Dilantin), or primidone (Mysoline).

This list is not complete and there may be other drugs that can interact with nisoldipine. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor. Keep a list with you of all the medicines you use and show this list to any doctor or other healthcare provider who treats you.

Where can I get more information?

Your pharmacist can provide more information about nisoldipine.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2012 Cerner Multum, Inc. Version: 4.04. Revision date: 12/15/2010.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Healthwise

Side Effects Centers

توزیع کنندگان این دارو
شرکت های تولید کننده یا وارد کننده دارو

دارونـــما
نوآوری برای سلامت

طراحی و اجرا M.Ramezani
ارتباط با ما Info@darunama.com